Rapidly healing flow diverters using magnetic cell targeting for intracranial aneurysm treatment
使用磁性细胞靶向治疗颅内动脉瘤的快速愈合分流器
基本信息
- 批准号:10508348
- 负责人:
- 金额:$ 21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAneurysmArteriesAutologousBiocompatible MaterialsBiologicalBloodBlood flowCathetersCellsCircle of WillisClinicalClinical ResearchClinical TreatmentComplicationCoronaryDataDevicesDistalElastasesEmbolismEndothelial CellsEndotheliumEvaluationFibrinFutureGoalsHemorrhageImpaired healingInternal carotid artery structureIntracranial AneurysmInvestigationIschemic StrokeLabelLeadLifeMagnetic nanoparticlesMagnetismMeasuresMechanicsMesenchymal Stem CellsModelingMorbidity - disease rateNeckOperative Surgical ProceduresOryctolagus cuniculusOutcomeParentsPatient CarePersonsPreclinical TestingPrincipal InvestigatorPropertyReproducibilityResearchResearch ProposalsRiskRuptureRuptured AneurysmSafetySideSiteStainless SteelStatistical MethodsStentsSurfaceTechniquesTechnologyTestingTherapeutic AgentsTherapeutic EmbolizationThromboembolismThrombosisTranslational ResearchTubular formationUnited StatesVascular GraftWorkbiomaterial compatibilityclinical applicationclinically relevantferritefirst-in-humanhealinghemocompatibilityimprovedimproved outcomein vivoinnovationmagnetic fieldmetallicityminimally invasivemortalitymultidisciplinarynanoparticle deliverynext generationnovelresponserestorationsafety and feasibilitysafety testingside effectstandard of caretargeted deliverytargeted treatmentthrombotictranslational approach
项目摘要
Project Summary
This application focuses on advancing the field of intracranial flow diversion, that currently constitutes
approximately one-third of the treatment of unruptured intracranial aneurysms. There remain key limitations to
the technology that hinder expansion of the clinical application of these transformational devices, which to date
are limited in scope to unruptured, proximal aneurysms along the internal carotid artery. One major barrier is
device-related thrombosis, which can lead to thrombotic or embolic ischemic stroke. This requires administration
of dual anti-platelet therapy, which has the serious side effect of bleeding. Another major barrier is delayed
healing and aneurysm occlusion, which precludes treatment of acutely ruptured aneurysms and necessitates
prolonged anti-platelet therapy. We will break down these barriers to expanded utility by 1) developing a
ferromagnetic flow diverter to enable magnetic targeting of therapeutic agents and 2) testing the safety and
feasibility of rapid device healing by magnetic targeting of autologous endothelial cells. Studies have shown that
endothelialization of the aneurysm neck is critical for long term complete aneurysm occlusion and anti-platelet
therapy can be safely discontinued. We envision that, with our proposed approach, we will facilitate application
of novel, next-generation devices in ruptured aneurysms and in aneurysms distal to the Circle of Willis, and will
minimize thromboembolic risk. We have previously developed magnetic devices including stents, stent-grafts,
and vascular grafts and demonstrated their ability to capture and retain magnetically-labeled endothelial cells.
We will extend our magnetic cell targeting technologies to the application of rapid endothelialization of flow
diverters. Our robust and reproducible methods of statistical evaluation will directly assess 1) device integrity
and functionality, 2) device biocompatibility and hemocompatibility, 3) device magnetic properties, 4) magnetic
cell capture and retention to the devices, and 5) safety and feasibility of rapid endotheliazation and aneurysm
occlusion of magnetically endothelialized flow diverters in an in vivo aneurysm model. The discoveries from this
hypothesis-driven, multidisciplinary, clinical-translational research will provide a robust understanding of the
benefits conferred by rapid endothelization of flow diverters used to treat intracranial aneurysms. The goal of
this research is to reduce the complication rate associated with device-related thrombosis, prolonged anti-platelet
therapy, and delayed aneurysm healing and occlusion. If successful, neurointerventionalists will be able to use
flow diverters to treat a broader range of aneurysms safely and effectively. Optimizing outcomes and minimizing
complications will significantly improve patient care and save lives. A ferromagnetic flow diverter will also enable
future investigations of targeted delivery of other therapeutic agents. For example, fibrin for rapid aneurysm
occlusion, mesenchymal stem cells for rapid healing, and anti-platelet therapy to localize the effects and reduce
systemic bleeding risk. Such investigations have the potential to be transformative in the treatment of intracranial
aneurysms by significantly improving upon the current standard of care.
项目摘要
该应用程序的重点是推进颅内血流导向领域,目前构成
约占未破裂颅内动脉瘤治疗的三分之一。仍然存在关键限制,
阻碍这些转换装置临床应用扩展的技术,
局限于沿着颈内动脉沿着的未破裂的近端动脉瘤。一个主要障碍是
器械相关血栓形成,可能导致血栓性或栓塞性缺血性卒中。这需要行政管理
双重抗血小板治疗,有严重的出血副作用。另一个主要障碍是延迟
愈合和动脉瘤闭塞,这妨碍了急性破裂动脉瘤的治疗,
长期抗血小板治疗。我们将打破这些障碍,以扩大效用1)开发一个
铁磁分流器,以实现治疗剂的磁性靶向,以及2)测试安全性,
通过磁靶向自体内皮细胞实现快速器械愈合的可行性。研究表明
动脉瘤颈的内皮化对于长期完全动脉瘤闭塞和抗血小板至关重要
可以安全地停止治疗。我们设想,通过我们提出的方法,
新一代器械用于破裂动脉瘤和Willis环远端动脉瘤,
最大程度降低血栓栓塞风险。我们之前已经开发了磁性装置,包括支架,支架移植物,
和血管移植物,并证明了它们捕获和保留磁性标记的内皮细胞的能力。
我们将把我们的磁性细胞靶向技术扩展到血流的快速内皮化应用中,
转移者我们稳健且可重复的统计评价方法将直接评估1)器械完整性
2)器械生物相容性和血液相容性,3)器械磁性,4)磁性
细胞捕获和保留到装置,以及5)快速内皮化和动脉瘤的安全性和可行性
体内动脉瘤模型中磁性内皮化血流导向装置的闭塞。从中得到的发现
假设驱动,多学科,临床转化研究将提供一个强大的理解,
用于治疗颅内动脉瘤的血流导向装置的快速内皮化带来的益处。的目标
本研究旨在降低与器械相关血栓形成相关的并发症发生率,
治疗和延迟动脉瘤愈合和闭塞。如果成功,神经介入医生将能够使用
血流导向装置可安全有效地治疗更广泛的动脉瘤。优化成果,
并发症将显著改善患者护理并挽救生命。铁磁分流器还将使
其他治疗剂的靶向递送的未来研究。例如,纤维蛋白用于快速动脉瘤
闭塞,用于快速愈合的间充质干细胞,以及抗血小板治疗,以定位效应并减少
全身出血风险。这些研究有可能在颅内肿瘤的治疗中起到革命性的作用。
通过显著改善当前的护理标准来治疗动脉瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ramanathan Kadirvel其他文献
Ramanathan Kadirvel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ramanathan Kadirvel', 18)}}的其他基金
Rapidly healing flow diverters using magnetic cell targeting for intracranial aneurysm treatment
使用磁性细胞靶向治疗颅内动脉瘤的快速愈合分流器
- 批准号:
10629368 - 财政年份:2022
- 资助金额:
$ 21万 - 项目类别:
Computational and Biological Approach to Flow Diversion
分流的计算和生物学方法
- 批准号:
8216809 - 财政年份:2011
- 资助金额:
$ 21万 - 项目类别:
Computational and Biological Approach to Flow Diversion
分流的计算和生物学方法
- 批准号:
8335380 - 财政年份:2011
- 资助金额:
$ 21万 - 项目类别:
Computational and Biological Approach to Flow Diversion
分流的计算和生物学方法
- 批准号:
8533042 - 财政年份:2011
- 资助金额:
$ 21万 - 项目类别:
Computational and Biological Approach to Flow Diversion
分流的计算和生物学方法
- 批准号:
8716821 - 财政年份:2011
- 资助金额:
$ 21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21万 - 项目类别:
Research Grant